For the medication supply in Switzerland has occurred in the case of an emergency. Even without the epidemic. For common diseases such as high blood pressure or Diabetes drugs acute not available. This is not about temporarily the case, but has tapered in the last few months, and generally become a permanent condition. The defect has structural reasons.
High revenues, especially new therapies, in which you have due to patent protection, the competitive advantage of pharmaceutical companies. The Basler group, Novartis, reaching around with his division for innovative drugs, a operating profit margin of 22.6 percent, while its generics Division, Sandoz, this is only 13.5 percent.
In the case of the price fixing, the authorities of honor breakthrough therapies for previously incurable diseases. Classic medicines for widespread diseases are just as important and often life-saving. Nevertheless, it comes to bottlenecks.
That the patent protection for generics is expired, and can be manufactured by many companies, exacerbated, paradoxically, the Problem of the delivery problems. It is precisely because the market here is the price pressure is high. The raw materials for the production to be as cheap as possible and come from China. But there are delivery problems because of chemical factories to be closed. Due to quality problems and environmental reasons. Cause of the Swiss of medication shortages, and the climate is so.
What would be the recipe against the bottlenecks? Generics have to be expensive. And expensive drugs cheaper. Thus, the cash costs will explode.
Created: 15.11.2019, 22:02 PM
